Researchers analyzed data from a clinical trial involving 1,270 participants aged 65 and older who identified as non-Hispanic Black or Hispanic. The study looked at the effects of taking a daily 100-mg dose of aspirin compared to a placebo. The primary goal was to see if aspirin could reduce the loss of disability-free survival, which includes death, persistent physical disability, or dementia.
The results showed that aspirin was associated with a lower risk of these conditions compared to a placebo. However, the benefit was not the same for everyone. The study found that the benefit was most significant in a specific group predicted to have the highest benefit. In contrast, the group predicted to have the lowest benefit did not show a significant reduction in risk.
It is important to note that these findings come from a post-hoc analysis, which means the researchers looked at the data after the trial was completed. Because of this method, the evidence is not yet certain enough to change standard medical practice. These results require further validation before they can be used to guide clinical decisions for patients.
